Barghout will succeed Andrew Weiss. She will lead the Palo Alto, California-based company’s business strategy and organization in a new direction, according to the company. The goal is to commercialize ReCor’s Paradise ultrasound renal denervation (uRDN) system that treats hypertension.
“I am honored to lead the extraordinary team at ReCor at an exciting time in the company’s growth,” Barghout said in a news release. “High blood pressure is a leading contributor to cardiovascular disease burden worldwide, resulting in increased patient risk and higher costs to health systems.
She added: “We believe our Paradise uRDN technology to be a true game changer in improving hypertension therapy, with the potential to offer a new option for physicians to help improve blood pressure outcomes for their patients on a global scale.”
A veteran of Siemens Healthineers and Terumo
Barghout has more than 20 years of experience leading global businesses in the medical device industry. She most recently was SVP and head of advanced therapies at Siemens Healthineers. There, she led the image-guided therapy business in North America. She has also held numerous leadership roles over the years at Terumo Cardiovascular.
“She is a highly experienced leader with a track record of commercial success across a range of medical device businesses, coupled with extensive experience in global leadership,” said Noriko Tojo, executive director of ReCor Medical’s parent company Otsuka Holdings. “We are very excited for Ms. Barghout to lead ReCor into its next phase of global growth. Her deep commercial experience and adept leadership make her ideal to build on the technology development and clinical trial successes of the ReCor team, guiding the business to realize its therapeutic and commercial potential..
Tojo thanks Weiss for his “outstanding leadership and countless contributions over the past 10 years.”
More about ReCor Medical and its renal denervation system
ReCor Medical’s Paradise uRDN System has the CE mark for hypertension treatment. It’s an investigational device in the U.S. and Japan. ReCor previously said that it plans to submit the results of its Radiance clinical studies to the FDA. The plan has been for the submission to be part of a premarket approval request. The company has also initiated the Global Paradise System registry in the EU with plans for global expansion.
In November, ReCor said the Paradise treatment showed consistent and significant blood pressure reductions in an analysis of pooled data from three Radiance randomized hypertension studies.
